



Psychoactive Substances Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-31	122	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Psychoactive Substances market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Psychoactive Substances market is projected to increase from US\$ million in 2026 to US\$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Psychoactive Substances market is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

Asia Pacific: the Psychoactive Substances market is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Psychoactive Substances include Alpha-CAT, AusCann Group Holdings Pty Ltd., Cannabics Pharmaceuticals Inc., Cape Bouvard Technologies Pty Ltd, Cyrelian Pty Ltd., Enecta., GD Pharma, GW Pharmaceuticals PLC. and MedReleaf Australia, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Psychoactive Substances market in terms of revenue (US\$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US\$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Psychoactive Substances.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Psychoactive Substances Market by Company

Alpha-CAT

AusCann Group Holdings Pty Ltd.

Cannabics Pharmaceuticals Inc.

Cape Bouvard Technologies Pty Ltd

Cyrelan Pty Ltd.

Enecta.

GD Pharma

GW Pharmaceuticals PLC.

MedReleaf Australia

Teewinot Life Sciences

Tilray

Zynerba Pharmaceuticals

Psychoactive Substances Segment by Type

Cannabinoids

Hallucinogens

Stimulants

Depressants

Psychoactive Substances Segment by Application

Neuropathic Disorders

Spasticity

Cancer

Psychoactive Substances Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psychoactive Substances market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Psychoactive Substances and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psychoactive Substances.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4:

Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5:

Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6:

Detailed analysis of Psychoactive Substances companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Psychoactive Substances by Type
 - 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
 - 2.2.2 Cannabinoids
 - 2.2.3 Hallucinogens
 - 2.2.4 Stimulants
 - 2.2.5 Depressants
- 2.3 Psychoactive Substances by Application
 - 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.3.2 Neuropathic Disorders
 - 2.3.3 Spasticity
 - 2.3.4 Cancer
- 2.4 Assumptions and Limitations

3 Psychoactive Substances Breakdown Data by Type

- 3.1 Global Psychoactive Substances Historic Market Size by Type (2021-2026)
- 3.2 Global Psychoactive Substances Forecasted Market Size by Type (2027-2032)

4 Psychoactive Substances Breakdown Data by Application

- 4.1 Global Psychoactive Substances Historic Market Size by Application (2021-2026)
- 4.2 Global Psychoactive Substances Forecasted Market Size by Application (2027-2032)

5 Global Growth Trends

- 5.1 Global Psychoactive Substances Market Perspective (2021-2032)
- 5.2 Global Psychoactive Substances Growth Trends by Region
 - 5.2.1 Global Psychoactive Substances Market Size by Region: 2021 VS 2025 VS 2032
 - 5.2.2 Psychoactive Substances Historic Market Size by Region (2021-2026)
 - 5.2.3 Psychoactive Substances Forecasted Market Size by Region (2027-2032)
- 5.3 Psychoactive Substances Market Dynamics
 - 5.3.1 Psychoactive Substances Industry Trends
 - 5.3.2 Psychoactive Substances Market Drivers
 - 5.3.3 Psychoactive Substances Market Challenges
 - 5.3.4 Psychoactive Substances Market Restraints

6 Market Competitive Landscape by Players

- 6.1 Global Top Psychoactive Substances Players by Revenue

- 6.1.1 Global Top Psychoactive Substances Players by Revenue (2021-2026)
 - 6.1.2 Global Psychoactive Substances Revenue Market Share by Players (2021-2026)
 - 6.2 Global Psychoactive Substances Industry Players Ranking, 2023 VS 2024 VS 2025
 - 6.3 Global Key Players of Psychoactive Substances Head Office and Area Served
 - 6.4 Global Psychoactive Substances Players, Product Type & Application
 - 6.5 Global Psychoactive Substances Manufacturers Established Date
 - 6.6 Global Psychoactive Substances Market CR5 and HHI
 - 6.7 Global Players Mergers & Acquisition
-

7 North America

- 7.1 North America Psychoactive Substances Market Size (2021-2032)
 - 7.2 North America Psychoactive Substances Market Growth Rate by Country: 2021 VS 2025 VS 2032
 - 7.3 North America Psychoactive Substances Market Size by Country (2021-2026)
 - 7.4 North America Psychoactive Substances Market Size by Country (2027-2032)
 - 7.5 United States
 - 7.5 United States
 - 7.6 Canada
 - 7.7 Mexico
-

8 Europe

- 8.1 Europe Psychoactive Substances Market Size (2021-2032)
 - 8.2 Europe Psychoactive Substances Market Growth Rate by Country: 2021 VS 2025 VS 2032
 - 8.3 Europe Psychoactive Substances Market Size by Country (2021-2026)
 - 8.4 Europe Psychoactive Substances Market Size by Country (2027-2032)
 - 8.5 Germany
 - 8.6 France
 - 8.7 U.K.
 - 8.8 Italy
 - 8.9 Spain
 - 8.10 Russia
 - 8.11 Netherlands
 - 8.12 Nordic Countries
-

9 Asia-Pacific

- 9.1 Asia-Pacific Psychoactive Substances Market Size (2021-2032)
 - 9.2 Asia-Pacific Psychoactive Substances Market Growth Rate by Country: 2021 VS 2025 VS 2032
 - 9.3 Asia-Pacific Psychoactive Substances Market Size by Country (2021-2026)
 - 9.4 Asia-Pacific Psychoactive Substances Market Size by Country (2027-2032)
 - 9.5 China
 - 9.6 Japan
 - 9.7 South Korea
 - 9.8 India
 - 9.9 Australia
 - 9.10 China Taiwan
 - 9.11 Southeast Asia
-

10 South America

- 10.1 South America Psychoactive Substances Market Size (2021-2032)
- 10.2 South America Psychoactive Substances Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Psychoactive Substances Market Size by Country (2021-2026)
- 10.4 South America Psychoactive Substances Market Size by Country (2027-2032)

- 10.5 Brazil
 - 10.6 Argentina
 - 10.7 Chile
 - 10.8 Colombia
 - 10.9 Peru
-

11 Middle East & Africa

- 11.1 Middle East & Africa Psychoactive Substances Market Size (2021-2032)
 - 11.2 Middle East & Africa Psychoactive Substances Market Growth Rate by Country: 2021 VS 2025 VS 2032
 - 11.3 Middle East & Africa Psychoactive Substances Market Size by Country (2021-2026)
 - 11.4 Middle East & Africa Psychoactive Substances Market Size by Country (2027-2032)
 - 11.5 Saudi Arabia
 - 11.6 Israel
 - 11.7 United Arab Emirates
 - 11.8 Turkey
 - 11.9 Iran
 - 11.10 Egypt
-

12 Players Profiled

- 12.1 Alpha-CAT
 - 12.1.1 Alpha-CAT Company Information
 - 12.1.2 Alpha-CAT Business Overview
 - 12.1.3 Alpha-CAT Revenue in Psychoactive Substances Business (2021-2026)
 - 12.1.4 Alpha-CAT Psychoactive Substances Product Portfolio
 - 12.1.5 Alpha-CAT Recent Developments
- 12.2 AusCann Group Holdings Pty Ltd.
 - 12.2.1 AusCann Group Holdings Pty Ltd. Company Information
 - 12.2.2 AusCann Group Holdings Pty Ltd. Business Overview
 - 12.2.3 AusCann Group Holdings Pty Ltd. Revenue in Psychoactive Substances Business (2021-2026)
 - 12.2.4 AusCann Group Holdings Pty Ltd. Psychoactive Substances Product Portfolio
 - 12.2.5 AusCann Group Holdings Pty Ltd. Recent Developments
- 12.3 Cannabics Pharmaceuticals Inc.
 - 12.3.1 Cannabics Pharmaceuticals Inc. Company Information
 - 12.3.2 Cannabics Pharmaceuticals Inc. Business Overview
 - 12.3.3 Cannabics Pharmaceuticals Inc. Revenue in Psychoactive Substances Business (2021-2026)
 - 12.3.4 Cannabics Pharmaceuticals Inc. Psychoactive Substances Product Portfolio
 - 12.3.5 Cannabics Pharmaceuticals Inc. Recent Developments
- 12.4 Cape Bouvard Technologies Pty Ltd
 - 12.4.1 Cape Bouvard Technologies Pty Ltd Company Information
 - 12.4.2 Cape Bouvard Technologies Pty Ltd Business Overview
 - 12.4.3 Cape Bouvard Technologies Pty Ltd Revenue in Psychoactive Substances Business (2021-2026)
 - 12.4.4 Cape Bouvard Technologies Pty Ltd Psychoactive Substances Product Portfolio
 - 12.4.5 Cape Bouvard Technologies Pty Ltd Recent Developments
- 12.5 Cyrelian Pty Ltd.
 - 12.5.1 Cyrelian Pty Ltd. Company Information
 - 12.5.2 Cyrelian Pty Ltd. Business Overview
 - 12.5.3 Cyrelian Pty Ltd. Revenue in Psychoactive Substances Business (2021-2026)
 - 12.5.4 Cyrelian Pty Ltd. Psychoactive Substances Product Portfolio
 - 12.5.5 Cyrelian Pty Ltd. Recent Developments
- 12.6 Enecta.

12.6.1 Enecta. Company Information

12.6.2 Enecta. Business Overview

12.6.3 Enecta. Revenue in Psychoactive Substances Business (2021-2026)

12.6.4 Enecta. Psychoactive Substances Product Portfolio

12.6.5 Enecta. Recent Developments

12.7 GD Pharma

12.7.1 GD Pharma Company Information

12.7.2 GD Pharma Business Overview

12.7.3 GD Pharma Revenue in Psychoactive Substances Business (2021-2026)

12.7.4 GD Pharma Psychoactive Substances Product Portfolio

12.7.5 GD Pharma Recent Developments

12.8 GW Pharmaceuticals PLC.

12.8.1 GW Pharmaceuticals PLC. Company Information

12.8.2 GW Pharmaceuticals PLC. Business Overview

12.8.3 GW Pharmaceuticals PLC. Revenue in Psychoactive Substances Business (2021-2026)

12.8.4 GW Pharmaceuticals PLC. Psychoactive Substances Product Portfolio

12.8.5 GW Pharmaceuticals PLC. Recent Developments

12.9 MedReleaf Australia

12.9.1 MedReleaf Australia Company Information

12.9.2 MedReleaf Australia Business Overview

12.9.3 MedReleaf Australia Revenue in Psychoactive Substances Business (2021-2026)

12.9.4 MedReleaf Australia Psychoactive Substances Product Portfolio

12.9.5 MedReleaf Australia Recent Developments

12.10 Teewinot Life Sciences

12.10.1 Teewinot Life Sciences Company Information

12.10.2 Teewinot Life Sciences Business Overview

12.10.3 Teewinot Life Sciences Revenue in Psychoactive Substances Business (2021-2026)

12.10.4 Teewinot Life Sciences Psychoactive Substances Product Portfolio

12.10.5 Teewinot Life Sciences Recent Developments

12.11 Tilray

12.11.1 Tilray Company Information

12.11.2 Tilray Business Overview

12.11.3 Tilray Revenue in Psychoactive Substances Business (2021-2026)

12.11.4 Tilray Psychoactive Substances Product Portfolio

12.11.5 Tilray Recent Developments

12.12 Zynerba Pharmaceuticals

12.12.1 Zynerba Pharmaceuticals Company Information

12.12.2 Zynerba Pharmaceuticals Business Overview

12.12.3 Zynerba Pharmaceuticals Revenue in Psychoactive Substances Business (2021-2026)

12.12.4 Zynerba Pharmaceuticals Psychoactive Substances Product Portfolio

12.12.5 Zynerba Pharmaceuticals Recent Developments

13 Report Conclusion

14 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Psychoactive Substances Market Size by Type (2021-2026) & (US\$ Million)
- Table 6: Global Psychoactive Substances Revenue Market Share by Type (2021-2026)
- Table 7: Global Psychoactive Substances Forecasted Market Size by Type (2027-2032) & (US\$ Million)
- Table 8: Global Psychoactive Substances Revenue Market Share by Type (2027-2032)
- Table 9: Global Psychoactive Substances Market Size by Application (2021-2026) & (US\$ Million)
- Table 10: Global Psychoactive Substances Revenue Market Share by Application (2021-2026)
- Table 11: Global Psychoactive Substances Forecasted Market Size by Application (2027-2032) & (US\$ Million)
- Table 12: Global Psychoactive Substances Revenue Market Share by Application (2027-2032)
- Table 13: Global Psychoactive Substances Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 14: Global Psychoactive Substances Market Size by Region (2021-2026) & (US\$ Million)
- Table 15: Global Psychoactive Substances Market Share by Region (2021-2026)
- Table 16: Global Psychoactive Substances Forecasted Market Size by Region (2027-2032) & (US\$ Million)
- Table 17: Global Psychoactive Substances Market Share by Region (2027-2032)
- Table 18: Psychoactive Substances Industry Trends
- Table 19: Psychoactive Substances Industry Drivers
- Table 20: Psychoactive Substances Industry Opportunities and Challenges
- Table 21: Psychoactive Substances Market Restraints
- Table 22: Global Top Psychoactive Substances Players by Revenue (US\$ Million) & (2021-2026)
- Table 23: Global Psychoactive Substances Revenue Market Share by Players (2021-2026)
- Table 24: Global Psychoactive Substances Industry Players Ranking, 2024 VS 2025 VS 2026
- Table 25: Global Key Players of Psychoactive Substances, Headquarters and Area Served
- Table 26: Global Psychoactive Substances Players, Product Type & Application
- Table 27: Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28: Global Psychoactive Substances by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 29: Players Mergers & Acquisitions, Expansion Plans
- Table 30: North America Psychoactive Substances Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 31: North America Psychoactive Substances Market Size by Country (2021-2026) & (US\$ Million)
- Table 32: North America Psychoactive Substances Market Size by Country (2027-2032) & (US\$ Million)
- Table 33: Europe Psychoactive Substances Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 34: Europe Psychoactive Substances Market Size by Country (2021-2026) & (US\$ Million)
- Table 35: Europe Psychoactive Substances Market Size by Country (2027-2032) & (US\$ Million)
- Table 36: Asia Pacific Psychoactive Substances Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 37: Asia Pacific Psychoactive Substances Market Size by Region (2021-2026) & (US\$ Million)
- Table 38: Asia Pacific Psychoactive Substances Market Size by Country (2027-2032) & (US\$ Million)
- Table 39: South America Psychoactive Substances Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 40: South America Psychoactive Substances Market Size by Country (2021-2026) & (US\$ Million)
- Table 41: South America Psychoactive Substances Market Size by Country (2027-2032) & (US\$ Million)
- Table 42: Middle East & Africa Psychoactive Substances Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 43: Middle East & Africa Psychoactive Substances Market Size by Country (2021-2026) & (US\$ Million)
- Table 44: Middle East & Africa Psychoactive Substances Market Size by Country (2027-2032) & (US\$ Million)
- Table 45: Alpha-CAT Company Information
- Table 46: Alpha-CAT Business Overview
- Table 47: Alpha-CAT Revenue in Psychoactive Substances Business (2021-2026) & (US\$ Million)
- Table 48: Alpha-CAT Psychoactive Substances Product Portfolio
- Table 49: Alpha-CAT Recent Developments
- Table 50: AusCann Group Holdings Pty Ltd. Company Information
- Table 51: AusCann Group Holdings Pty Ltd. Business Overview
- Table 52: AusCann Group Holdings Pty Ltd. Revenue in Psychoactive Substances Business (2021-2026) & (US\$ Million)
- Table 53: AusCann Group Holdings Pty Ltd. Psychoactive Substances Product Portfolio
- Table 54: AusCann Group Holdings Pty Ltd. Recent Developments

- Table 55: Cannabics Pharmaceuticals Inc. Company Information
- Table 56: Cannabics Pharmaceuticals Inc. Business Overview
- Table 57: Cannabics Pharmaceuticals Inc. Revenue in Psychoactive Substances Business (2021-2026) & (US\$ Million)
- Table 58: Cannabics Pharmaceuticals Inc. Psychoactive Substances Product Portfolio
- Table 59: Cannabics Pharmaceuticals Inc. Recent Developments
- Table 60: Cape Bouvard Technologies Pty Ltd Company Information
- Table 61: Cape Bouvard Technologies Pty Ltd Business Overview
- Table 62: Cape Bouvard Technologies Pty Ltd Revenue in Psychoactive Substances Business (2021-2026) & (US\$ Million)
- Table 63: Cape Bouvard Technologies Pty Ltd Psychoactive Substances Product Portfolio
- Table 64: Cape Bouvard Technologies Pty Ltd Recent Developments
- Table 65: Cyrelian Pty Ltd. Company Information
- Table 66: Cyrelian Pty Ltd. Business Overview
- Table 67: Cyrelian Pty Ltd. Revenue in Psychoactive Substances Business (2021-2026) & (US\$ Million)
- Table 68: Cyrelian Pty Ltd. Psychoactive Substances Product Portfolio
- Table 69: Cyrelian Pty Ltd. Recent Developments
- Table 70: Enecta. Company Information
- Table 71: Enecta. Business Overview
- Table 72: Enecta. Revenue in Psychoactive Substances Business (2021-2026) & (US\$ Million)
- Table 73: Enecta. Psychoactive Substances Product Portfolio
- Table 74: Enecta. Recent Developments
- Table 75: GD Pharma Company Information
- Table 76: GD Pharma Business Overview
- Table 77: GD Pharma Revenue in Psychoactive Substances Business (2021-2026) & (US\$ Million)
- Table 78: GD Pharma Psychoactive Substances Product Portfolio
- Table 79: GD Pharma Recent Developments
- Table 80: GW Pharmaceuticals PLC. Company Information
- Table 81: GW Pharmaceuticals PLC. Business Overview
- Table 82: GW Pharmaceuticals PLC. Revenue in Psychoactive Substances Business (2021-2026) & (US\$ Million)
- Table 83: GW Pharmaceuticals PLC. Psychoactive Substances Product Portfolio
- Table 84: GW Pharmaceuticals PLC. Recent Developments
- Table 85: MedReleaf Australia Company Information
- Table 86: MedReleaf Australia Business Overview
- Table 87: MedReleaf Australia Revenue in Psychoactive Substances Business (2021-2026) & (US\$ Million)
- Table 88: MedReleaf Australia Psychoactive Substances Product Portfolio
- Table 89: MedReleaf Australia Recent Developments
- Table 90: Teewinot Life Sciences Company Information
- Table 91: Teewinot Life Sciences Business Overview
- Table 92: Teewinot Life Sciences Revenue in Psychoactive Substances Business (2021-2026) & (US\$ Million)
- Table 93: Teewinot Life Sciences Psychoactive Substances Product Portfolio
- Table 94: Teewinot Life Sciences Recent Developments
- Table 95: Tilray Company Information
- Table 96: Tilray Business Overview
- Table 97: Tilray Revenue in Psychoactive Substances Business (2021-2026) & (US\$ Million)
- Table 98: Tilray Psychoactive Substances Product Portfolio
- Table 99: Tilray Recent Developments
- Table 100: Zynerba Pharmaceuticals Company Information
- Table 101: Zynerba Pharmaceuticals Business Overview
- Table 102: Zynerba Pharmaceuticals Revenue in Psychoactive Substances Business (2021-2026) & (US\$ Million)
- Table 103: Zynerba Pharmaceuticals Psychoactive Substances Product Portfolio
- Table 104: Zynerba Pharmaceuticals Recent Developments
- Table 105: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Psychoactive Substances Product Image
- Figure 5: Global Psychoactive Substances Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 6: Global Psychoactive Substances Market Share by Type: 2025 VS 2032
- Figure 7: Cannabinoids Product
- Figure 8: Hallucinogens Product
- Figure 9: Stimulants Product
- Figure 10: Depressants Product

- Figure 11: Global Psychoactive Substances Market Size by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 12: Global Psychoactive Substances Market Share by Application: 2025 VS 2032
- Figure 13: Neuropathic Disorders Product
- Figure 14: Spasticity Product
- Figure 15: Cancer Product
- Figure 16: Global Psychoactive Substances Market Size (US\$ Million), Year-over-Year: 2021-2032
- Figure 17: Global Psychoactive Substances Market Size, (US\$ Million), 2021 VS 2025 VS 2032
- Figure 18: Global Psychoactive Substances Market Share by Region: 2025 VS 2032
- Figure 19: Global Psychoactive Substances Market Share by Players in 2025
- Figure 20: Global Psychoactive Substances Manufacturers Established Date
- Figure 21: Global Top 5 and 10 Psychoactive Substances Players Market Share by Revenue in 2025
- Figure 22: Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 23: North America Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 24: North America Psychoactive Substances Market Share by Country (2021-2032)
- Figure 25: United States Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 26: Canada Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 27: Mexico Psychoactive Substances Market Share by Country (2021-2032)
- Figure 28: Europe Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 29: Europe Psychoactive Substances Market Share by Country (2021-2032)
- Figure 30: Germany Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 31: France Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 32: U.K. Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 33: Italy Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 34: Spain Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 35: Russia Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 36: Netherlands Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 37: Nordic Countries Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 38: Asia-Pacific Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 39: Asia-Pacific Psychoactive Substances Market Share by Country (2021-2032)
- Figure 40: China Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 41: Japan Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 42: South Korea Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 43: India Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 44: India Psychoactive Substances Market Share by Country (2021-2032)
- Figure 45: Australia Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 46: China Taiwan Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 47: Southeast Asia Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 48: South America Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 49: South America Psychoactive Substances Market Share by Country (2021-2032)
- Figure 50: Brazil Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 51: Argentina Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 52: Chile Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 53: Colombia Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 54: Peru Psychoactive Substances Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 55: Alpha-CAT Revenue Growth Rate in Psychoactive Substances Business (2021-2026)
- Figure 56: AusCann Group Holdings Pty Ltd. Revenue Growth Rate in Psychoactive Substances Business (2021-2026)
- Figure 57: Cannabics Pharmaceuticals Inc. Revenue Growth Rate in Psychoactive Substances Business (2021-2026)
- Figure 58: Cape Bouvard Technologies Pty Ltd Revenue Growth Rate in Psychoactive Substances Business (2021-2026)
- Figure 59: Cyrelian Pty Ltd. Revenue Growth Rate in Psychoactive Substances Business (2021-2026)
- Figure 60: Enecta. Revenue Growth Rate in Psychoactive Substances Business (2021-2026)
- Figure 61: GD Pharma Revenue Growth Rate in Psychoactive Substances Business (2021-2026)
- Figure 62: GW Pharmaceuticals PLC. Revenue Growth Rate in Psychoactive Substances Business (2021-2026)
- Figure 63: MedReleaf Australia Revenue Growth Rate in Psychoactive Substances Business (2021-2026)
- Figure 64: Teewinot Life Sciences Revenue Growth Rate in Psychoactive Substances Business (2021-2026)
- Figure 65: Tilray Revenue Growth Rate in Psychoactive Substances Business (2021-2026)
- Figure 66: Zynerba Pharmaceuticals Revenue Growth Rate in Psychoactive Substances Business (2021-2026)